<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Pharmacology CornerPharmacology animations | Pharmacology Corner</title>
	<atom:link href="http://pharmacologycorner.com/category/pharmacology-animations/feed/" rel="self" type="application/rss+xml" />
	<link>http://pharmacologycorner.com</link>
	<description>Pharmacology education for healthcare professionals</description>
	<lastBuildDate>Thu, 03 May 2012 13:25:22 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>The coagulation cascade</title>
		<link>http://pharmacologycorner.com/coagulation-cascade/</link>
		<comments>http://pharmacologycorner.com/coagulation-cascade/#comments</comments>
		<pubDate>Wed, 20 Oct 2010 21:49:47 +0000</pubDate>
		<dc:creator>Flavio Guzmán, MD</dc:creator>
				<category><![CDATA[Antiplatelet agents]]></category>
		<category><![CDATA[Antithrombotics]]></category>
		<category><![CDATA[Cardiovascular]]></category>
		<category><![CDATA[Pharmacology animations]]></category>
		<category><![CDATA[Thrombolytics]]></category>

		<guid isPermaLink="false">http://pharmacologycorner.com/?p=2620</guid>
		<description><![CDATA[Coagulation cascade: several resources (videos, animations and tutorials) depicting coagulation factors and pathways.]]></description>
			<content:encoded><![CDATA[<p>This article is an approach to the physiology of coagulation. Several resources  (videos, animations and tutorials) are presented to help the reader learn the key coagulation factors and pathways.</p>
<h2 style="text-align: left;">Coagulation cascade: extrinsic, intrinsic and common pathways differentiation</h2>
<p style="text-align: left;">Video animation contents:</p>
<ul>
<li>Intrinsic pathway</li>
<li>Extrinsic pathway (endothelium exposure to VIIa factor).</li>
<li>Common pathway</li>
</ul>
<p><object width="432" height="316" classid="clsid:d27cdb6e-ae6d-11cf-96b8-444553540000" codebase="http://download.macromedia.com/pub/shockwave/cabs/flash/swflash.cab#version=6,0,40,0"><param name="quality" value="high" /><param name="src" value="http://pharmacologycorner.com/animations/coag-hopk.swf" /><embed width="432" height="316" type="application/x-shockwave-flash" src="http://pharmacologycorner.com/animations/coag-hopk.swf" quality="high" /></object></p>
<p style="text-align: left;"><a href="http://www.hopkinsmedicine.org/hematology/Coagulation.swf" rel="nofollow">Extrinsic, intinsic and common pathways</a></p>
<h2>Hemostasis overview</h2>
<p>The following animation depicts the process of hemostasis after endothelial damage (vasoconstriction, platelet adhesion, activation, interaction between coagulation factors and thrombin activation).</p>
<p><img class="size-full wp-image-2619 alignnone" title="hemostasis" src="http://pharmacologycorner.com/wp-content/uploads/2009/10/hemostasis.jpg" alt="hemostasis" width="394" height="295" /></p>
<p style="text-align: left;"><a href="http://www.mhhe.com/biosci/esp/2002_general/Esp/folder_structure/tr/m1/s7/trm1s7_3.htm" rel="nofollow" target="_blank">Hemostasis</a></p>
<h2 style="text-align: left;">Coagulation cascade learning module</h2>
<p style="text-align: left;">This tutorial features interactive exercises and animations that help understand the role of coagulation cascade factors and physiological hemostatic processes.</p>
<p style="text-align: left;">It highlights clinical disorders on intrinsic and extrinsic pathways, with a special section overviewing Von Willebrand&#8217;s disease.</p>
<p style="text-align: left;"><img class="size-full wp-image-2622 alignnone" title="clotting_cascade" src="http://pharmacologycorner.com/wp-content/uploads/2009/10/clotting_cascade.jpg" alt="clotting_cascade" width="377" height="251" /></p>
<p style="text-align: left;"><a href="http://meds.queensu.ca/medicine/deptmed/hemonc/anemia/coag/CCLM.swf" rel="nofollow"> Clotting cascade learning module </a></p>
<h2 style="text-align: left;">Coagulation factors commented</h2>
<p>This animation focuses exclusively on the coagulation cascade factors and its sequence of activation. It emphasises biochemical and laboratory aspects.</p>
<p><img class="size-full wp-image-2623 alignnone" title="clotting_factors_2" src="http://pharmacologycorner.com/wp-content/uploads/2009/10/clotting_factors_2.jpg" alt="clotting_factors_2" width="375" height="270" /></p>
<p style="text-align: left;"><a href="http://labcorp.savvior.com/flash/coagulation_interactive.swf" rel="nofollow">Coagulation factors</a></p>
<div id="_mcePaste" style="overflow: hidden; position: absolute; left: -10000px; top: 1181px; width: 1px; height: 1px;"><object width="560" height="340" classid="clsid:d27cdb6e-ae6d-11cf-96b8-444553540000" codebase="http://download.macromedia.com/pub/shockwave/cabs/flash/swflash.cab#version=6,0,40,0"><param name="allowFullScreen" value="true" /><param name="allowscriptaccess" value="always" /><param name="src" value="http://www.youtube.com/v/qO7Kkm6jf9w&amp;hl=es&amp;fs=1&amp;" /><param name="allowfullscreen" value="true" /><embed width="560" height="340" type="application/x-shockwave-flash" src="http://www.youtube.com/v/qO7Kkm6jf9w&amp;hl=es&amp;fs=1&amp;" allowFullScreen="true" allowscriptaccess="always" allowfullscreen="true" /></object></div>
]]></content:encoded>
			<wfw:commentRss>http://pharmacologycorner.com/coagulation-cascade/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Animation showing the Jak-Stat signalling pathway mechanism</title>
		<link>http://pharmacologycorner.com/animation-showing-the-jak-stat-signalling-pathway-mechanism/</link>
		<comments>http://pharmacologycorner.com/animation-showing-the-jak-stat-signalling-pathway-mechanism/#comments</comments>
		<pubDate>Sat, 12 Jun 2010 21:12:39 +0000</pubDate>
		<dc:creator>Flavio Guzmán, MD</dc:creator>
				<category><![CDATA[Hematology, cancer chemotherapy and related]]></category>
		<category><![CDATA[Pharmacology animations]]></category>
		<category><![CDATA[intracelullar signaling]]></category>
		<category><![CDATA[Jak-Stat]]></category>
		<category><![CDATA[myeloproliferative disorders]]></category>

		<guid isPermaLink="false">http://pharmacologycorner.com/animation-showing-the-jak-stat-signalling-pathway-mechanism/</guid>
		<description><![CDATA[The Jak-Stat pathway has recently attracted researchers’ attention. This has been motivated by the fact that this pathway is a potential target of future agents for the treatment of myeloproliferative disorders such as: polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. The animation below depicts the Jak-Stat signalling pathway mechanism: As mentioned above, there...]]></description>
			<content:encoded><![CDATA[<p>The <strong>Jak-Stat pathway</strong> has recently attracted researchers’ attention. This has been motivated by the fact that this pathway is a potential target of future agents for the treatment of myeloproliferative disorders such as: polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.</p>
<p>The animation below depicts the <strong>Jak-Stat </strong>signalling <strong>pathway</strong> mechanism:</p>
<p><object classid="clsid:d27cdb6e-ae6d-11cf-96b8-444553540000" width="490" height="490" codebase="http://download.macromedia.com/pub/shockwave/cabs/flash/swflash.cab#version=6,0,40,0"><param name="quality" value="high" /><param name="src" value="http://pharmacologycorner.com/animations/jakstats_27.swf" /><embed type="application/x-shockwave-flash" width="490" height="490" src="http://pharmacologycorner.com/animations/jakstats_27.swf" quality="high"></embed></object></p>
<p>As mentioned above, there are some expectations on the future of JAK STAT pathway in pharmacology:</p>
<blockquote><p>JAK2 Inhibitors</p>
<p>Despite the success of imatinib mesylate in the treatment of CML, the genetic basis of the other major myeloproliferative disorders (polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis) has, until recently, remained obscure. It is now apparent that a common activating mutation in JAK2 (V617F) underlies the aberrant signaling and proliferation in most cases, although how one mutation leads to this spectrum of disorders remains unclear. The V617F mutation is found in the pseudokinase domain of JAK2, and disruption of this autoinhibitory region leads to unchecked activity of the kinase. Cells containing the JAK2 V617F mutation are growth inhibited and undergo apoptosis in response to specific JAK2 inhibitors in vitro. Thus, <strong>JAK2 inhibitors are under development for the treatment of polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis</strong>.</p>
<p>Source: <a href="http://www.amazon.com/gp/product/0781783550?ie=UTF8&amp;tag=farmaymedic-20&amp;linkCode=as2&amp;camp=1789&amp;creative=390957&amp;creativeASIN=0781783550">Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy: D. Golan et al. LWW. 2007</a></p></blockquote>
<p>Related links</p>
<p><a rel="nofollow" href="http://www.jci.org/articles/view/15644">Series Introduction: JAK-STAT signaling in human disease. Christian W. Schindler. J. Clin. Invest. 109(9): 1133-1137 (2002)</a></p>
<p><a href="http://www.jci.org/articles/view/15786">JAK-STAT signaling in asthma. Alessandra B. Pernis and Paul B. Rothman. J. Clin. Invest. 109(10): 1279-1283 (2002)</a></p>
]]></content:encoded>
			<wfw:commentRss>http://pharmacologycorner.com/animation-showing-the-jak-stat-signalling-pathway-mechanism/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
		</item>
		<item>
		<title>Animation: NRTIs mechanism of action</title>
		<link>http://pharmacologycorner.com/animation-nrti-mechanism-of-action/</link>
		<comments>http://pharmacologycorner.com/animation-nrti-mechanism-of-action/#comments</comments>
		<pubDate>Sun, 13 Dec 2009 16:23:56 +0000</pubDate>
		<dc:creator>Flavio Guzmán, MD</dc:creator>
				<category><![CDATA[Antiretrovirals]]></category>
		<category><![CDATA[Antivirals]]></category>
		<category><![CDATA[HIV- AIDS & Infectious diseases]]></category>
		<category><![CDATA[Pharmacology animations]]></category>
		<category><![CDATA[mechanism of action]]></category>
		<category><![CDATA[NNRTI]]></category>

		<guid isPermaLink="false">http://pharmacologycorner.com/?p=2849</guid>
		<description><![CDATA[Nucleoside analog reverse transcriptase inhibitors (NRTIs) are nucleoside analogues that act as competitive inhibitors of HIV-1 reverse transcriptase. As shown in the animation, these drugs compete with nucleoside triphosphates for access to reverse transcriptase. All NRTIs lack a 3-hydroxyl group; thus, their incorporation into a growing DNA chain results in its termination. They require intracytoplasmic...]]></description>
			<content:encoded><![CDATA[<div id="attachment_2869" class="wp-caption alignleft" style="width: 137px"><img class="size-full wp-image-2869" title="nrti_mechanism_action_antiretrovirals" src="http://pharmacologycorner.com/wp-content/uploads/2009/12/nrti_mechanism_action_antiretrovirals.jpg" alt="nrti_mechanism_action_antiretrovirals" width="127" height="200" /><p class="wp-caption-text">NRTIs mechanism</p></div>
<p>Nucleoside analog reverse transcriptase inhibitors (NRTIs) are nucleoside analogues that act as competitive inhibitors of HIV-1 reverse transcriptase. As shown in the animation, these drugs compete with nucleoside triphosphates for access to reverse transcriptase.</p>
<p>All NRTIs lack a 3-hydroxyl group; thus, their incorporation into a growing DNA chain results in its termination. They require intracytoplasmic activation via phosphorylation by cellular enzymes to the triphosphate form. Most have activity against HIV-2 as well as HIV-1.</p>
<h3>NRTIs mechanism of action</h3>
<div><object classid="clsid:d27cdb6e-ae6d-11cf-96b8-444553540000" width="300" height="500" codebase="http://download.macromedia.com/pub/shockwave/cabs/flash/swflash.cab#version=6,0,40,0"><param name="src" value="http://pharmacologycorner.com/animations/nnrti.swf" /><embed type="application/x-shockwave-flash" width="300" height="500" src="http://pharmacologycorner.com/animations/nnrti.swf"></embed></object></div>
<h3>List of NRTIs</h3>
<ul>
<li>Zidovudine or azidothymidine (AZT) (also called ZDV): first approved drug in its class.</li>
<li>Didanosine (ddI): second FDA-approved drug for the treatment of HIV infection.</li>
<li>Tenofovir (TDF): first nucleotide analog. It has significant drug interactions.</li>
<li>Lamivudine (3TC): also used in the treatment of HBV infection.</li>
<li>Emtricitabine (FTC): acts as an inhibitor of HBV and HIV transcriptase.</li>
<li>Abacavir (ABC): a guanosine analog.</li>
</ul>
<h3>Animations depicting mechanisms of other antiretrovirals</h3>
<ul>
<li><a title="Protease inhibitors" href="http://pharmacologycorner.com/hiv-protease-inhibitors-animation-showing-their-mechanism-of-action/">HIV protease inhibitors</a></li>
<li><a title="HIV fusion inhibitors" href="http://pharmacologycorner.com/hiv-fusion-inhibitors-mechanism-of-action-a-video-animation/">HIV fusion inhibitors</a></li>
</ul>
<h3>References</h3>
<p><a rel="nofollow" href="http://www.amazon.com/gp/product/0071604057?ie=UTF8&amp;tag=farmaymedic-20&amp;linkCode=as2&amp;camp=1789&amp;creative=390957&amp;creativeASIN=0071604057"><em>Katzung,  B. “<strong>Basic &amp; Clinical Pharmacology</strong>”, 11th Edition. Mc Graw Hill  Medical: 2009</em></a></p>
<h3>Recommended reading</h3>
<ul>
<li><strong><a rel="nofollow" href="http://www.amazon.com/gp/product/1930808577?ie=UTF8&amp;tag=farmaymedic-20&amp;linkCode=as2&amp;camp=1789&amp;creative=390957&amp;creativeASIN=1930808577">The  Sanford Guide to HIV/AIDS Therapy 2010</a></strong></li>
<li><strong><a rel="nofollow" href="http://www.amazon.com/gp/product/1930808577?ie=UTF8&amp;tag=farmaymedic-20&amp;linkCode=as2&amp;camp=1789&amp;creative=390957&amp;creativeASIN=1930808577">Mandell, Douglas, and Bennett&#8217;s Principles and Practice of Infectious Diseases (2009)</a></strong></li>
<li><strong><a rel="nofollow" href="http://www.amazon.com/gp/product/0763777099?ie=UTF8&amp;tag=farmaymedic-20&amp;linkCode=as2&amp;camp=1789&amp;creative=390957&amp;creativeASIN=0763777099">HIV Essentials 2010</a><img style="border: none !important; margin: 0px !important;" src="http://www.assoc-amazon.com/e/ir?t=farmaymedic-20&amp;l=as2&amp;o=1&amp;a=0763777099" border="0" alt="" width="1" height="1" /></strong></li>
<li><strong><a rel="nofollow" href="http://www.amazon.com/gp/product/3639176790?ie=UTF8&amp;tag=farmaymedic-20&amp;linkCode=as2&amp;camp=1789&amp;creative=390957&amp;creativeASIN=3639176790">HIV Diversity and Antiretroviral Resistance: Epidemiology, Recombination, HAART</a><img style="border: none !important; margin: 0px !important;" src="http://www.assoc-amazon.com/e/ir?t=farmaymedic-20&amp;l=as2&amp;o=1&amp;a=3639176790" border="0" alt="" width="1" height="1" /></strong></li>
</ul>
<h5>About the animation author</h5>
<p><img class="alignleft" title="author2" src="http://pharmacologycorner.com/wp-content/uploads/2009/09/author2-300x228.jpg" alt=" Dr. Kaiser enjoys riding his Harley-Davidson Low Ride" width="223" height="169" /></p>
<p><span style="color: #ffffff;">.</span>Dr. Gary Kaiser is a Professor of Microbiology at The Community College of Baltimore County, Catonsville Campus located in Baltimore, Maryland. Make sure you visit his excellent microbiology website: <a href="http://student.ccbcmd.edu/~gkaiser/goshp.html"><strong>The Grapes of Staph.</strong><br />
</a><br />
<span style="color: #ffffff;">.</span></p>
]]></content:encoded>
			<wfw:commentRss>http://pharmacologycorner.com/animation-nrti-mechanism-of-action/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>An excellent animation on the mechanisms of drug addiction</title>
		<link>http://pharmacologycorner.com/mechanisms-drug-addiction-animation/</link>
		<comments>http://pharmacologycorner.com/mechanisms-drug-addiction-animation/#comments</comments>
		<pubDate>Sat, 10 Oct 2009 17:17:50 +0000</pubDate>
		<dc:creator>Flavio Guzmán, MD</dc:creator>
				<category><![CDATA[Pain drug therapy]]></category>
		<category><![CDATA[Pharmacology animations]]></category>
		<category><![CDATA[Psychiatry]]></category>
		<category><![CDATA[Videos]]></category>

		<guid isPermaLink="false">http://pharmacologycorner.com/?p=2482</guid>
		<description><![CDATA[The Genetic Science Learning Center at University of Utah developed an excellent animation depicting the mechanisms of addiction of most drugs of abuse. They use a cartoon-like approach to show biochemical changes in mouse brains.]]></description>
			<content:encoded><![CDATA[<p>The Genetic Science Learning Center at University of Utah developed an excellent animation depicting the mechanisms of addiction of most drugs of abuse. They use a cartoon-like approach to show molecular changes in mouse brains.<br />
<img class="aligncenter size-full wp-image-2483" title="drug_addiction_mechanisms" src="http://pharmacologycorner.com/wp-content/uploads/2009/09/drug_addiction_mechanisms.jpg" alt="drug_addiction_mechanisms" width="445" height="319" /></p>
<p style="text-align: center;"><strong><a href="http://learn.genetics.utah.edu/content/addiction/drugs/mouse.html" target="_blank">Watch animation</a></strong></p>
<p>They approach the following topics related to the neurobiology of drug addiction.</p>
<ul>
<li><a href="../methamphetamine-mechanism-addiction-brain-reward-system/">Methamphetamine</a> actions on dopamine vesicles.</li>
<li>LSD action on <a href="http://pharmacologycorner.com/serotonin-5ht-receptors-agonists-antagonist/">serotonin</a> receptors.</li>
<li>Heroin effects on opioid receptors .</li>
<li>How marijuana interacts with the cannabinoid system and its receptors.</li>
<li>Activation of the GABA-A <a href="../video-animation-mechanism-of-ionotropic-receptors-or-ligand-gated-ion-channels-lgics/">ionotropic receptor</a> by alcohol.</li>
<li>Cocaine action on dopamine reuptake.</li>
</ul>
<p>This blog has a related post that explains <a href="http://pharmacologycorner.com/video-molecular-mechanism-nicotine-addiction/">nicotine addiction mechanism</a> through a 3-D video animation.</p>
]]></content:encoded>
			<wfw:commentRss>http://pharmacologycorner.com/mechanisms-drug-addiction-animation/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
		</item>
		<item>
		<title>Vancomycin mechanism of action: an animation</title>
		<link>http://pharmacologycorner.com/vancomycin-mechanism-action-animation/</link>
		<comments>http://pharmacologycorner.com/vancomycin-mechanism-action-animation/#comments</comments>
		<pubDate>Fri, 02 Oct 2009 01:33:26 +0000</pubDate>
		<dc:creator>Flavio Guzmán, MD</dc:creator>
				<category><![CDATA[Antibiotics]]></category>
		<category><![CDATA[HIV- AIDS & Infectious diseases]]></category>
		<category><![CDATA[Pharmacology animations]]></category>
		<category><![CDATA[vancomycin]]></category>

		<guid isPermaLink="false">http://pharmacologycorner.com/?p=2488</guid>
		<description><![CDATA[Vancomycin is a tricyclic glycopeptide that has gained clinical importance thanks to its effectiveness against organisms such as MRSA and enterococci. It has activity against Gram-positive rods and cocci, Gram-negative rods are resistant to its bactericidal action. Some clinical uses of IV vancomycin include treatment of infective endocarditis and sepsis caused by MRSA. Since vancomycin...]]></description>
			<content:encoded><![CDATA[<p>Vancomycin is a tricyclic glycopeptide that has gained clinical importance thanks to its effectiveness against organisms such as MRSA and enterococci. It has <strong>activity</strong> against Gram-positive rods and cocci, Gram-negative rods are resistant to its bactericidal action.</p>
<p>Some <strong>clinical uses</strong> of IV vancomycin include treatment of infective endocarditis and sepsis caused by MRSA. Since vancomycin is poorly absorbed,  it is used only in treatment of enterocolitis caused by <em>C. difficile</em>.</p>
<p>Vancomycin <strong>adverse effects</strong> include skin flushing (red-man syndrome), fever, chills and phlebitis at the infusion site. Ototoxicity and nephrotoxicity must be kept in mind when treating patients that are receiving other drugs.</p>
<h3>Mechanism of action</h3>
<p><img class="alignleft size-full wp-image-2525" title="vancomycin_mechanism_action" src="http://pharmacologycorner.com/wp-content/uploads/2009/09/vancomycin_mechanism_action.jpg" alt="vancomycin_mechanism_action" width="177" height="136" />As you can see in the animation below, vancomycin binds to the pentapeptides of the peptidoglycan monomers and prevents the transglycosylation step in peptidoglycan polymerization. This weakens the cell wall and damages the underlying cell membrane.</p>
<p><object id="vancomycin" classid="clsid:d27cdb6e-ae6d-11cf-96b8-444553540000" width="550" height="495" codebase="http://download.macromedia.com/pub/shockwave/cabs/flash/swflash.cab#version=6,0,40,0"><param name="src" value="http://farmacologiaymedicina.com/files/vancomycin.swf" /><param name="name" value="vancomycin" /><param name="bgcolor" value="#ffffff" /><param name="align" value="middle" /><param name="quality" value="high" /><embed id="vancomycin" type="application/x-shockwave-flash" width="550" height="495" src="http://farmacologiaymedicina.com/files/vancomycin.swf" quality="high" align="middle" bgcolor="#ffffff" name="vancomycin"></embed></object></p>
<h3>About the animation author</h3>
<div id="attachment_2490" class="wp-caption alignleft" style="width: 233px"><img class="size-medium wp-image-2490" title="author2" src="http://pharmacologycorner.com/wp-content/uploads/2009/09/author2-300x228.jpg" alt=" Dr. Kaiser enjoys riding his Harley-Davidson Low Ride" width="223" height="169" /><p class="wp-caption-text"> Dr. Kaiser enjoys riding his Harley-Davidson Low Ride</p></div>
<p><span style="color: #ffffff;">.<br />
</span></p>
<p><span style="color: #ffffff;">.</span></p>
<p>Dr. Gary Kaiser is a Professor of Microbiology at The Community College of Baltimore County, Catonsville Campus located in Baltimore, Maryland. Make sure you visit his excellent microbiology website: <a href="http://student.ccbcmd.edu/~gkaiser/goshp.html"><strong>The Grapes of Staph.</strong><br />
</a><br />
<span style="color: #ffffff;">.<br />
</span><br />
<span style="color: #ffffff;">.<br />
</span><br />
<span style="color: #ffffff;">.</span></p>
<h3>References</h3>
<p><em>Golan, David E (editor). “Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy”, 2nd edition. LWW: 2008.</em><br />
<em><br />
</em><em> Harvey, R; Champe, P (series editors). “Lippincott illustrated reviews: Pharmacology”, 4th edition. LWW: 2009.</em></p>
<p><em> </em></p>
<p><a rel="nofollow" href="http://www.amazon.com/gp/product/1930808526?ie=UTF8&amp;tag=farmaymedic-20&amp;linkCode=as2&amp;camp=1789&amp;creative=390957&amp;creativeASIN=1930808526"><em>Gilbert, D;  Moellering R (editors) </em><em>&#8220;Sanford Guide to Antimicrobial Therapy&#8221;</em><em>, 39th edition. Antimicrobial therapy: 2009</em></a></p>
<p><em> </em></p>
<p><a rel="nofollow" href="http://www.amazon.com/gp/product/0781794641?ie=UTF8&amp;tag=farmaymedic-20&amp;linkCode=as2&amp;camp=1789&amp;creative=390957&amp;creativeASIN=0781794641"><em>Hauser, A. </em><em>&#8220;Antibiotic Basics for Clinicians: Choosing the Right Antibacterial Agent&#8221;</em><em>.1st edition. LWW:2007</em></a></p>
<p><em> </em></p>
<p><a rel="nofollow" href="http://www.amazon.com/gp/product/0763759597?ie=UTF8&amp;tag=farmaymedic-20&amp;linkCode=as2&amp;camp=1789&amp;creative=390957&amp;creativeASIN=0763759597"><em>Gallagher, J. &#8220;</em><em>Antibiotics Simp</em></a><em><a rel="nofollow" href="http://www.amazon.com/gp/product/0763759597?ie=UTF8&amp;tag=farmaymedic-20&amp;linkCode=as2&amp;camp=1789&amp;creative=390957&amp;creativeASIN=0763759597">lified&#8221;. 1st edition. Jones &amp; Bartlett Publishers: 2008</a></em><a rel="nofollow" href="http://www.amazon.com/gp/product/0763759597?ie=UTF8&amp;tag=farmaymedic-20&amp;linkCode=as2&amp;camp=1789&amp;creative=390957&amp;creativeASIN=0763759597"> </a></p>
]]></content:encoded>
			<wfw:commentRss>http://pharmacologycorner.com/vancomycin-mechanism-action-animation/feed/</wfw:commentRss>
		<slash:comments>4</slash:comments>
		</item>
		<item>
		<title>Video: molecular mechanisms of nicotine addiction</title>
		<link>http://pharmacologycorner.com/video-molecular-mechanism-nicotine-addiction/</link>
		<comments>http://pharmacologycorner.com/video-molecular-mechanism-nicotine-addiction/#comments</comments>
		<pubDate>Wed, 12 Aug 2009 22:27:00 +0000</pubDate>
		<dc:creator>Flavio Guzmán, MD</dc:creator>
				<category><![CDATA[Pharmacodynamics]]></category>
		<category><![CDATA[Pharmacology animations]]></category>
		<category><![CDATA[Videos]]></category>

		<guid isPermaLink="false">http://pharmacologycorner.com/?p=1621</guid>
		<description><![CDATA[This video explains the pathophysiologic changes behind nicotine addiction, it identifies nicotinic acetylcholine receptor as a key protein for the development of dependence.]]></description>
			<content:encoded><![CDATA[<p>This video explains the pathophysiologic changes behind nicotine addiction, it identifies nicotinic acetylcholine receptor as  a key protein for the development of dependence.</p>
<div id="scid:5737277B-5D6D-4f48-ABFC-DD9C333F4C5D:a9aec22a-7419-4b10-bc80-79604bc3703b" class="wlWriterEditableSmartContent" style="display: inline; float: none; margin: 0px; padding: 0px;">
<div style="text-align: center;"><object classid="clsid:d27cdb6e-ae6d-11cf-96b8-444553540000" width="425" height="355" codebase="http://download.macromedia.com/pub/shockwave/cabs/flash/swflash.cab#version=6,0,40,0"><param name="src" value="http://www.youtube.com/v/797WAV3kZhQ&amp;hl=es&amp;fs=1&amp;hl=en" /><embed type="application/x-shockwave-flash" width="425" height="355" src="http://www.youtube.com/v/797WAV3kZhQ&amp;hl=es&amp;fs=1&amp;hl=en"></embed></object></div>
</div>
<p>Transcript of the video narration:</p>
<p>&#8220;Although nicotine can interact with a variety of receptor at numerous tissues, it is its interaction with specific receptors in the brain that creates the dependence associated with smoking.</p>
<p>Within the midbrain, nicotine interacts with the alpha 4 beta 2 <a href="http://pharmacologycorner.com/video-molecular-mechanism-nicotine-addiction/"><strong>nicotinic acetylcholine receptor</strong></a>. Acetylcholine is the natural ligand for this receptors. However, nicotine also an acetylcholine receptor agonist, has a higher affinity for the α4β2 (alpha 4 beta 2) receptors. Located on postsynaptic neurons, these receptors are comprised by two α4 and three β2 subunits that form a channel for transporting ions through the membrane.</p>
<p>When two molecules of nicotine or another ligand engage binding sites within the <a href="http://pharmacologycorner.com/video-animation-mechanism-of-ionotropic-receptors-or-ligand-gated-ion-channels-lgics/">ionotropic receptor</a>, the ion channel is activated. Looking into the receptor, we see that it is closed, but activation by ligand triggers channel opening for the passage of calcium, sodium and potassium ions.This generates action potentials to the reward area of the brain. Here, the impulse stimulates the release of neurotransmitters including dopamine. Dopamine triggers additional signaling events that stimulate the reward circuit generating short feelings of well-being, increased attention and improved mood. Every time tobacco is used, dopamine levels surge. However, nicotine is eliminated rather rapidly, causing dopamine levels to decline. The result: a craving for more nicotine.</p>
<p>With continued use, α4β2 (alpha 4 beta 2) nicotinic receptors undergo complex adaptive changes including up regulation and <a href="http://pharmacologycorner.com/pharmacodynamics-definitions-receptor-desensitization/">desensitization</a>. Over time, these and other downstream changes contribute to a stronger need for nicotine stimulation to achieve the rewards of smoking.&#8221;</p>
]]></content:encoded>
			<wfw:commentRss>http://pharmacologycorner.com/video-molecular-mechanism-nicotine-addiction/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Animation showing digoxin mechanism of action. Effects at molecular, tissue and system levels</title>
		<link>http://pharmacologycorner.com/animation-showing-digoxin-mechanism-of-action-effects-at-molecular-tissue-and-system-levels/</link>
		<comments>http://pharmacologycorner.com/animation-showing-digoxin-mechanism-of-action-effects-at-molecular-tissue-and-system-levels/#comments</comments>
		<pubDate>Sun, 05 Apr 2009 22:01:05 +0000</pubDate>
		<dc:creator>Flavio Guzmán, MD</dc:creator>
				<category><![CDATA[Cardiovascular]]></category>
		<category><![CDATA[Pharmacology animations]]></category>
		<category><![CDATA[Videos]]></category>
		<category><![CDATA[animation]]></category>
		<category><![CDATA[atrial fibrillation]]></category>
		<category><![CDATA[atrial flutter]]></category>
		<category><![CDATA[digitalis]]></category>
		<category><![CDATA[Digitek]]></category>
		<category><![CDATA[digoxin]]></category>
		<category><![CDATA[glycoside]]></category>
		<category><![CDATA[heart failure]]></category>
		<category><![CDATA[Lanoxin]]></category>
		<category><![CDATA[mechanism of action]]></category>

		<guid isPermaLink="false">http://pharmacologycorner.com/animation-showing-digoxin-mechanism-of-action-effects-at-molecular-tissue-and-system-levels/</guid>
		<description><![CDATA[Mechanism of action of digoxin (Lanoxin) reviewed: animation and excerpts of a pharmacology textbook on the pharmacological effects of this cardiac glycoside for heart failure.]]></description>
			<content:encoded><![CDATA[<p>This animation explains the positive inotropic mechanism of digoxin (a cardiac glycoside extracted from the plant <em>Digitalis Lanata)</em> and its pharmacological effects at molecular, tissue and systemic levels.</p>
<p>Digoxin is indicated in the treatment of atrial fibrillation, atrial flutter and heart failure (currently it is not a first line treatment).</p>
<p><object classid="clsid:d27cdb6e-ae6d-11cf-96b8-444553540000" width="500" height="500" codebase="http://download.macromedia.com/pub/shockwave/cabs/flash/swflash.cab#version=6,0,40,0"><param name="src" value="http://pharmacologycorner.com/animations/digoxin-mechanism-of-action.swf" /><param name="quality" value="high" /><embed type="application/x-shockwave-flash" width="500" height="500" src="http://pharmacologycorner.com/animations/digoxin-mechanism-of-action.swf" quality="high"></embed></object><a name="gohere"></a></p>
<p>This excerpt explains digoxin effects on cardiac contractility and autonomic regulation of the electrophysiologic properties of the heart.</p>
<p>From: Principles of Pharmacology: <a href="http://www.amazon.com/Principles-Pharmacology-Pathophysiologic-Basis-Therapy/dp/0781783550/ref=pd_bbs_2?ie=UTF8&amp;s=books&amp;qid=1238968390&amp;sr=8-2">The Pathophysiologic Basis of Drug Therapy, 2nd edition. D.Golan</a></p>
<blockquote><p>Digoxin</p>
<p>Digoxin is a selective inhibitor of the plasma membrane sodium pump.</p>
<p><span id="more-1371"></span>Cardiac myocytes exposed to digoxin extrude less sodium, leading to a rise in intracellular sodium concentration. In turn, the increase in intracellular sodium concentration alters the equilibrium of the sodium–calcium exchanger: calcium efflux is decreased because the gradient for sodium entry is decreased, while calcium influx is increased because the gradient for sodium efflux is increased. The net result is a rise in the intracellular calcium concentration. In response to this rise, the SR of the digoxin-treated cell sequesters more calcium. When the digoxin-treated cell depolarizes in response to an action potential, there is more Ca<sup>2+</sup> available to bind troponin C, and tension development during contraction is facilitated.</p></blockquote>
<blockquote><p>In addition to its effects on myocardial contractility, digoxin exerts autonomic effects through its binding to sodium pumps in the plasma membranes of neurons in the central and peripheral nervous systems. These effects include inhibition of sympathetic nervous outflow, sensitization of baroreceptors, and increased parasympathetic (vagal) tone. Digoxin also alters the electrophysiologic properties of the heart by a direct action on the cardiac conduction system. At therapeutic doses, digoxin decreases automaticity at the AV node, prolonging the effective refractory period of AV nodal tissue and slowing conduction velocity through the node. These combined vagotonic and electrophysiologic properties underlie the use of digoxin in the treatment of patients with atrial fibrillation and rapid ventricular response rates; both the decreased automaticity of AV nodal tissue and the decreased conduction velocity through the node increase the degree of AV block, and thereby decrease the ventricular response rate.</p>
<p>In contrast to its effects at the AV node, digoxin enhances automaticity of the infranodal (His–Purkinje) conduction system. These divergent effects at the AV node and His– Purkinje system explain the characteristic electrophysiologic disturbance of complete heart block with accelerated junctional or accelerated idioventricular escape rhythm (referred to as “regularized” atrial fibrillation) in patients with digoxin toxicity.</p></blockquote>
<p>Digoxin is commonly marketed under the trade names Lanoxin, Digitek, and Lanoxicaps</p>
]]></content:encoded>
			<wfw:commentRss>http://pharmacologycorner.com/animation-showing-digoxin-mechanism-of-action-effects-at-molecular-tissue-and-system-levels/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharmacokinetics video and PowerPoint: volume of distribution and factors that affect it</title>
		<link>http://pharmacologycorner.com/pharmacokinetics-video-and-powerpoint-volume-of-distribution-and-factors-that-affect-it/</link>
		<comments>http://pharmacologycorner.com/pharmacokinetics-video-and-powerpoint-volume-of-distribution-and-factors-that-affect-it/#comments</comments>
		<pubDate>Fri, 27 Mar 2009 23:08:48 +0000</pubDate>
		<dc:creator>Flavio Guzmán, MD</dc:creator>
				<category><![CDATA[Pharmacokinetics]]></category>
		<category><![CDATA[Pharmacology animations]]></category>
		<category><![CDATA[Videos]]></category>
		<category><![CDATA[pharmacokinetics video]]></category>
		<category><![CDATA[total body water]]></category>
		<category><![CDATA[volume of distribution]]></category>

		<guid isPermaLink="false">http://pharmacologycorner.com/pharmacokinetics-video-and-powerpoint-volume-of-distribution-and-factors-that-affect-it/</guid>
		<description><![CDATA[Video showing determinants of drug distribution: protein binding, molecular weight, lipid solubility. PowerPoint slideshow analizing the meaning of volume of distribution.]]></description>
			<content:encoded><![CDATA[<p>Here I share with you some media to begin to understand the concept of drug distribution.</p>
<p>First, a video that analyzes the factors that affect drug distribution: protein binding, molecular weight and lipid solubility.</p>
<p>Authors: Nelson Caetano, Dr. Jef Bratberg. University of Rhode Island</p>
<div id="scid:5737277B-5D6D-4f48-ABFC-DD9C333F4C5D:4786f14c-feac-4caf-81e1-bb078b7cf04b" class="wlWriterEditableSmartContent" style="display: inline; float: none; margin: 0px; padding: 0px;">
<div><object width="425" height="355" classid="clsid:d27cdb6e-ae6d-11cf-96b8-444553540000" codebase="http://download.macromedia.com/pub/shockwave/cabs/flash/swflash.cab#version=6,0,40,0"><param name="src" value="http://www.youtube.com/v/8zYIEiXvSZY&amp;hl=es&amp;fs=1&amp;hl=en" /><embed width="425" height="355" type="application/x-shockwave-flash" src="http://www.youtube.com/v/8zYIEiXvSZY&amp;hl=es&amp;fs=1&amp;hl=en" /></object></div>
</div>
<p>A transcript of the explanatory text:</p>
<blockquote><p>Unbound drug passes freely through blood vessels and is distributed into the rest of the body. Protein bound drug is trapped within the vessel and is therefore unable to reach its intended sight of action.</p>
<p>Small drug molecules can freely diffuse out of the blood vessel while large drug molecules are confined to the plasma. Heparin is a good example of a drug like this.</p>
<p>Lipid solubility of a drug is a major component in determining its distribution, particularly on the brain. The blood brain barrier prevents the crossing of polarized molecules from capillaries to brain neurons.</p></blockquote>
<p>The slides below are part of a lecture I give about pharmacokinetics. I chose the slides that explain the meaning of the different values of volume of distribution.</p>
<p>A drug that has a volume of distribution near the plasma volume (e.g. 5 liters) is a drug distributed mainly in the intravascular space. A drug with a very high volume of distribution ( hundreds of liters) should guide us to think that is a drug that bind very strongly to a particular tissue.</p>
<p><object width="425" height="355" classid="clsid:d27cdb6e-ae6d-11cf-96b8-444553540000" codebase="http://download.macromedia.com/pub/shockwave/cabs/flash/swflash.cab#version=6,0,40,0"><param name="src" value="http://static.slidesharecdn.com/swf/ssplayer2.swf?doc=volumeofdistribution-090326222641-phpapp01&amp;stripped_title=volume-of-distribution" /><param name="allowfullscreen" value="true" /><embed width="425" height="355" type="application/x-shockwave-flash" src="http://static.slidesharecdn.com/swf/ssplayer2.swf?doc=volumeofdistribution-090326222641-phpapp01&amp;stripped_title=volume-of-distribution" allowfullscreen="true" /></object></p>
<div id="scid:fb3a1972-4489-4e52-abe7-25a00bb07fdf:55a26fd9-f2bf-4059-bccf-1927a70eaf8a" class="wlWriterEditableSmartContent" style="display: inline; float: none; margin: 0px; padding: 0px;">
<p>Download PPT file: <a href="http://pharmacologycorner.com/wp-content/uploads/2009/03/volumeofdistribution.ppt" target="_blank">Volume of distribution</a></p>
<h3>Recommended pharmacokinetics reading</h3>
<ul>
<li><strong><a href="http://www.amazon.com/gp/product/0070285276?ie=UTF8&amp;tag=farmaymedic-20&amp;linkCode=as2&amp;camp=1789&amp;creative=390957&amp;creativeASIN=0070285276" rel="nofollow">Pocket Guide: Pharmacokinetics Made Easy (2009)</a></strong></li>
<li><strong><a href="http://www.amazon.com/gp/product/0781779030?ie=UTF8&amp;tag=farmaymedic-20&amp;linkCode=as2&amp;camp=1789&amp;creative=390957&amp;creativeASIN=0781779030" rel="nofollow">Basic Clinical Pharmacokinetics (2009)</a></strong></li>
<li><strong><a href="http://www.amazon.com/gp/product/1585282413?ie=UTF8&amp;tag=farmaymedic-20&amp;linkCode=as2&amp;camp=1789&amp;creative=390957&amp;creativeASIN=1585282413" rel="nofollow">Concepts in Clinical Pharmacokinetics (2010)</a></strong></li>
<li><strong><a href="http://www.amazon.com/gp/product/1585281670?ie=UTF8&amp;tag=farmaymedic-20&amp;linkCode=as2&amp;camp=1789&amp;creative=390957&amp;creativeASIN=1585281670" rel="nofollow">Clinical Pharmacokinetics, 4th Edition (2008)</a></strong></li>
</ul>
</div>
]]></content:encoded>
			<wfw:commentRss>http://pharmacologycorner.com/pharmacokinetics-video-and-powerpoint-volume-of-distribution-and-factors-that-affect-it/feed/</wfw:commentRss>
		<slash:comments>6</slash:comments>
		</item>
		<item>
		<title>USMLE-like questions on antihypertensives</title>
		<link>http://pharmacologycorner.com/usmle-like-questions-on-antihypertensives/</link>
		<comments>http://pharmacologycorner.com/usmle-like-questions-on-antihypertensives/#comments</comments>
		<pubDate>Thu, 19 Feb 2009 04:10:51 +0000</pubDate>
		<dc:creator>Flavio Guzmán, MD</dc:creator>
				<category><![CDATA[Cardiovascular]]></category>
		<category><![CDATA[MCQs and quizzes for USMLE]]></category>
		<category><![CDATA[Pharmacology animations]]></category>

		<guid isPermaLink="false">http://pharmacologycorner.com/usmle-like-questions-on-antihypertensives/</guid>
		<description><![CDATA[These questions from the UMKC School of Medicine have a different degree of difficulty, but are useful to review pharmacology of hypertension. Antihypertensives Item Number: 11201   correct answer: 4  category: Antihypertensives 1.   Gynecomastia, hyperkalemia, and menstrual abnormalities are potential adverse effects associated with: A.  amiloride B.  captopril C.  triamterene D.  spironolactone 1. A,B,C 2. A,C...]]></description>
			<content:encoded><![CDATA[<p>These questions from the <a href="http://www.med.umkc.edu/pharm/">UMKC School of Medicine</a> have a different degree of difficulty, but are useful to review pharmacology of hypertension.</p>
<blockquote><p>Antihypertensives<br />
Item Number: 11201   correct answer: 4  category: Antihypertensives<br />
1.   Gynecomastia, hyperkalemia, and menstrual abnormalities are potential adverse<br />
effects associated with:<br />
A.  amiloride<br />
B.  captopril<br />
C.  triamterene<br />
D.  spironolactone<br />
1. A,B,C<br />
2. A,C<br />
3. B,D<br />
4. D only<br />
5. All are correct</p>
<p>Item Number: 11218   correct answer: 2  category: Antihypertensives<br />
2.   Diuretics which may result in hyperkalemia when used in a patient also<br />
receiving potassium supplementation include:<br />
A.  amiloride<br />
B.  mannitol<br />
C.  triamterene<br />
D.  bumetanide<br />
1. A,B,C<br />
2. A,C<br />
3. B,D<br />
4. D only<br />
5. All are correct</p>
<p><span id="more-1197"></span></p>
<p>Item Number: 11220   correct answer: 1  category: Antihypertensives<br />
3.   Metabolic alkalosis may be a complication of the administration of:<br />
A.  hydrochlorothiazide<br />
B.  bumetanide<br />
C.  furosemide<br />
D.  acetazolamide<br />
1. A,B,C<br />
2. A,C<br />
3. B,D<br />
4. D only<br />
5. All are correct</p>
<p>Item Number: 11244   correct answer: 2  category: Antihypertensives<br />
4.   Beta blockers which are relatively cardioselective include:<br />
A.  metoprolol<br />
B.  pindolol<br />
C.  atenolol<br />
D.  timolol<br />
1. A,B,C<br />
2. A,C<br />
3. B,D<br />
4. D only<br />
5. All are correct</p>
<p>Item Number: 11288   correct answer: 2  category: Antihypertensives<br />
5.   Reflex tachycardia is not likely to occur during therapy with:<br />
A.  clonidine<br />
B.  diazoxide<br />
C.  reserpine<br />
D.  minoxidil<br />
1. A,B,C<br />
2. A,C<br />
3. B,D<br />
4. D only<br />
5. All are correct</p>
<p>Item Number: 11308   correct answer: 3  category: Antihypertensives<br />
6.   Beta blockers which may be less likely to produce CNS-related adverse effects<br />
include<br />
A.  metoprolol<br />
B.  nadolol<br />
C.  timolol<br />
D.  atenolol<br />
1. A,B,C<br />
2. A,C<br />
3. B,D<br />
4. D only<br />
5. All are correct</p>
<p>Item Number: 11316   correct answer: 4  category: Antihypertensives<br />
7.   Guanadrel is pharmacologically similar to:<br />
A.  clonidine<br />
B.  guanabenz<br />
C.  methyldopa<br />
D.  guanethidine<br />
1. A,B,C<br />
2. A,C<br />
3. B,D<br />
4. D only<br />
5. All are correct</p>
<p>Item Number: 11335   correct answer: 1  category: Antihypertensives<br />
8.   Adverse effects associated with guanethidine include:<br />
A.  orthostatic hypotension<br />
B.  enhanced sensitivity to sympathomimetics<br />
C.  diarrhea<br />
D.  sedation<br />
1. A,B,C<br />
2. A,C<br />
3. B,D<br />
4. D only<br />
5. All are correct</p>
<p>Item Number: 11340   correct answer: 2  category: Antihypertensives<br />
9.   Adverse effects associated with hydralazine include:<br />
A.  reflex tachycardia<br />
B.  hypertrichosis<br />
C.  lupus syndrome<br />
D.  orthostatic hypotension<br />
1. A,B,C<br />
2. A,C<br />
3. B,D<br />
4. D only<br />
5. All are correct</p>
<p>Item Number: 11341   correct answer: 2  category: Antihypertensives<br />
10.   Risk factors associated with increased risk of toxicity during captopril<br />
therapy include:<br />
A.  bilateral renal artery stenosis<br />
B.  congestive heart failure<br />
C.  systemic lupus erythematosus<br />
D.  female gender<br />
1. A,B,C<br />
2. A,C<br />
3. B,D<br />
4. D only<br />
5. All are correct</p>
<p>Item Number: 684   correct answer: 4  category: Antihypertensives<br />
11.   Diazoxide, a drug used for treatment of hypertensive crises, is most closely<br />
related to:<br />
1. nitrofuran<br />
2. sulfonamides<br />
3. dopamine antagonists<br />
4. <a href="http://pharmacologycorner.com/video-animation-on-renal-physiology-and-diuretics-mechanism-of-action">thiazide diuretics</a><br />
5. nitrates</p>
<p>Item Number: 807   correct answer: 2  category: Antihypertensives<br />
12.   Which of the following drugs is(are) known to induce hyperuricemia and<br />
occasionally to bring about an acute gouty attack?<br />
1. salicylates (6 grams per day)<br />
2. chlorothiazide<br />
3. phenytoin<br />
4. spironolactone<br />
5. All of the above</p>
<p>Item Number: 1186   correct answer: 4  category: Antihypertensives<br />
13.   Undesirable side effects of reserpine include:<br />
1. bradycardia<br />
2. postural hypotension<br />
3. diarrhea<br />
4. All of the above<br />
5. None of the above</p>
<p>Item Number: 1858   correct answer: 3  category: Antihypertensives<br />
14.   Propranolol may cause all of the following EXCEPT:<br />
1. bradycardia<br />
2. bronchiolar constriction<br />
3. hyperglycemia<br />
4. reduced myocardial contractility<br />
5. prevention of the dilation of vessels caused by circulating epinephrine</p>
<p>Item Number: 2883   correct answer: 5  category: Antihypertensives<br />
15.   Alpha methyldopa has been used successfully in the control of hypertension.<br />
Side effects include all of the following, EXCEPT:<br />
1. positive direct Coomb&#8217;s test<br />
2. diarrhea<br />
3. hemolytic anemia<br />
4. fever<br />
5. nephrotic syndrome</p>
<p>Item Number: 3538   correct answer: 3  category: Antihypertensives<br />
16.   A 48-year old salesman with known hypertension complains of a decreasing<br />
annual income, a loss of &#8220;drive&#8221;, and a depressed outlook on life. His blood<br />
pressure is normal on medication. The antihypertensive drug most likely to be<br />
the cause of his new complaints is:<br />
1. hydralazine<br />
2. alpha methyldopa<br />
3. reserpine<br />
4. hydrochlorothiazide<br />
5. guanethidine</p>
<p>Item Number: 6258   correct answer: 1  category: Antihypertensives<br />
17.   Side effects of medications are often responsible for a patient not complying<br />
with the prescribed drug regimen.  An agent which has somnolence as a primary<br />
side effect is:<br />
1. methyldopa<br />
2. hydralazine<br />
3. guanethidine<br />
4. 1,2<br />
5. 1,3</p>
<p>Item Number: 6259   correct answer: 4  category: Antihypertensives<br />
18.   One of the mechanisms for &#8216;resistance&#8221; to an antihypertensive drug regimen is<br />
a retention of salt and water and an increase in extracellular fluid volume.<br />
Agents which have been shown to cause retention of salt and water include:<br />
1. methyldopa<br />
2. clonidine<br />
3. guanethidine<br />
4. All of the above<br />
5. 1,2</p>
<p>Item Number: 6273   correct answer: 4  category: Antihypertensives<br />
19.   Clonidine hydrochloride lowers blood pressure by reducing sympathetic tone.<br />
It is believed to act by inhibiting sympathetic outflow from the vasomotor<br />
center in the medulla.  A potentially serious adverse reaction that has been<br />
reported is:<br />
1. ventricular fibrillation<br />
2. anaphylaxis<br />
3. irreversible nephrotoxicity<br />
4. withdrawal syndrome resembling hypertensive crisis<br />
5. systemic lupus erythematosus</p>
<p>Item Number: 6274   correct answer: 4  category: Antihypertensives<br />
20.   Propranolol produces most of its important effects by antagonizing the beta<br />
adrenergic effects of catecholamines released by sympathetic nerve stimulation<br />
or from the adrenal medulla. It therefore results in all of the following<br />
EXCEPT:<br />
1. negative inotropic effect on the heart<br />
2. bronchoconstriction<br />
3. lowering plasma renin activity<br />
4. hyperglycemia<br />
5. negative chronotropic effect on the heart</p>
<p>Item Number: 7929   correct answer: 3  category: Antihypertensives<br />
21.   The antihypertensive agent most likely to increase cardiac output is:<br />
1. chlorothiazide<br />
2. reserpine<br />
3. hydralazine<br />
4. alpha-methyldopa<br />
5. guanethidine</p>
<p>Item Number: 8117   correct answer: 1  category: Antihypertensives<br />
22.   An agent which produces its antihypertensive effect by blocking autonomic<br />
ganglia, thus lowering the sympathetic tone of blood vessels, is:<br />
1. trimethaphan<br />
2. diazoxide<br />
3. <a href="http://pharmacologycorner.com/alpha-1-adrenergic-receptors-antagonists-blockers-mechanism-of-action-animation/">phenoxybenzamine </a><br />
4. reserpine<br />
5. alpha-methyldopa</p>
<p>Item Number: 8236   correct answer: 1  category: Antihypertensives<br />
23.   The most useful drugs in the long-term treatment of essential hypertension<br />
are:<br />
1. thiazide diuretics<br />
2. osmotic diuretics<br />
3. mercurial diuretics<br />
4. carbonic anhydrase inhibitors<br />
5. xanthine diuretics</p>
<p>Item Number: 8321   correct answer: 5  category: Antihypertensives<br />
24.   Antihypertensive agents that act primarily at arterioles include:<br />
1. hydralazine<br />
2. minoxidil<br />
3. diazoxide<br />
4. nitroglycerin<br />
5. 1,2,3</p>
<p>Item Number: 8332   correct answer: 1  category: Antihypertensives<br />
25.   Antihypertensive agents have different modes of action. The expected<br />
onset of action of IV nitroprusside is:<br />
1. seconds<br />
2. several minutes<br />
3. 15 to 30 minutes<br />
4. several hours<br />
5. 12 to 24 hours</p>
<p>Item Number: 8354   correct answer: 4  category: Antihypertensives<br />
26.   Antihypertensive agents must be used with caution.  The medical condition for<br />
which methyldopa is most contraindicated is:<br />
1. renal insufficiency<br />
2. coronary insufficiency<br />
3. mental depression<br />
4. liver disease<br />
5. asthma</p>
<p>Item Number: 8364   correct answer: 2  category: Antihypertensives<br />
27.   Antihypertensive agents must be used with caution. The medical condition for<br />
which hydralazine is most contraindicated is:<br />
1. renal insufficiency<br />
2. coronary insufficiency<br />
3. mental depression<br />
4. liver disease<br />
5. asthma</p>
<p>Item Number: 8375   correct answer: 3  category: Antihypertensives<br />
28.   Antihypertensive agents must be used with caution. The medical condition for<br />
which reserpine is most contraindicated is:<br />
1. renal insufficiency<br />
2. coronary insufficiency<br />
3. mental depression<br />
4. liver disease<br />
5. asthma</p>
<p>Item Number: 9618   correct answer: 5  category: Antihypertensives<br />
29.   Reduced tissue levels of norepinephrine may result from long-term treatment<br />
with:<br />
1. guanethidine<br />
2. reserpine<br />
3. alpha-methyl-tyrosine<br />
4. All of the above<br />
5. 1,2</p>
<p>Item Number: 11387   correct answer: 1  category: Antihypertensives<br />
30.   Propranolol is a potent blocker of beta-adrenergic sympathetic activity. It<br />
has been found to be detrimental, however, in patients with:<br />
1. bronchial asthma<br />
2. hypertension<br />
3. hyperthyroidism<br />
4. atrial fibrillation<br />
5. ventricular arrhythmias</p>
<p>Item Number: 13199   correct answer: 4  category: Antihypertensives<br />
31.   It is important to understand the mechanism of action of the various drugs<br />
used in the treatment of hypertension. The antihypertensive action of<br />
propranolol involves all of the following EXCEPT:<br />
1. decreased stroke volume<br />
2. inhibition of renin release<br />
3. central nervous system effect<br />
4. depletion of catecholamines<br />
5. decreased heart rate</p>
<p>Item Number: 13202   correct answer: 4  category: Antihypertensives<br />
32.   It is important to understand the side effects of the various antihypertensive<br />
agents. Drugs such as guanethidine that block the function of postganglionic<br />
adrenergic neurons may produce all of the following EXCEPT:<br />
1. orthostatic hypotension<br />
2. bradycardia<br />
3. retrograde ejaculation<br />
4. constipation<br />
5. dry mouth</p>
<p>Item Number: 13701   correct answer: 4  category: Antihypertensives<br />
33.   Propranolol is contraindicated in all of the following EXCEPT:<br />
1. bronchial asthma<br />
2. sinus bradycardia<br />
3. second or third degree heart block<br />
4. migraine headache prophylaxis<br />
5. congestive heart failure</p>
<p>Item Number: 13713   correct answer: 4  category: Antihypertensives<br />
34.   Which of the following diuretics has a greater antihypertensive activity?<br />
1. hydrochlorothiazide 50 mg<br />
2. chlorothiazide 500 mg<br />
3. spironolactone 100 mg<br />
4. all are equivalent antihypertensive agents<br />
5. 1,2</p>
<p>Item Number: 13717   correct answer: 2  category: Antihypertensives<br />
35.   A patient complains of headache and his blood pressure is 120/80. His<br />
medications include hydrochlorothiazide and hydralazine. Which of the<br />
following would seem most likely?<br />
1. The headaches are secondary to thiazide-induced hypokalemia<br />
2. The headaches are secondary to hydralazine therapy<br />
3. The headaches are probably unrelated to drug therapy<br />
4. The headaches are related to hydralazine-induced agranulocytosis<br />
5. 1,2</p>
<p>Item Number: 13718   correct answer: 4  category: Antihypertensives<br />
36.  A patient is admitted to the hospital for surgery and has been taking 2.4 mg<br />
of clonidine plus 50 mg hydrochlorothiazide daily for several months prior to<br />
surgery.  You would expect in this patient:<br />
1. A low likelihood of problems if the clonidine is continued<br />
2. A possibility of markedly increased blood pressure if the clonidine is<br />
stopped<br />
3. Severe postural hypotension if clonidine is discontinued abruptly<br />
4. 1,2<br />
5. 1,3</p>
<p>Item Number: 13719   correct answer: 5  category: Antihypertensives<br />
37.   Drugs which may have their effectiveness diminished if the patient<br />
concomitantly receives a tricyclic antidepressant include:<br />
1. hydralazine<br />
2. guanethidine<br />
3. clonidine<br />
4. 1,2<br />
5. 2,3</p>
<p>Item Number: 13720   correct answer: 4  category: Antihypertensives<br />
38.   Tachycardia is a prominent side effect of:<br />
1. diazoxide<br />
2. hydralazine<br />
3. clonidine<br />
4. 1,2<br />
5. 2,3</p>
<p>Item Number: 13722   correct answer: 2  category: Antihypertensives<br />
39.   All of the following statements concerning the use of sodium nitroprusside are<br />
true EXCEPT:<br />
1. it is metabolized to thiocyanate<br />
2. it must be given by rapid IV push injection<br />
3. it dilates both arterial and venous vessels<br />
4. 1,3<br />
5. 2,3</p>
<p>Item Number: 488   correct answer: 2  category: Antihypertensives<br />
40.   Chronic administration of ethacrynic acid without proper electrolyte<br />
management produces:<br />
1. potassium retention<br />
2. metabolic alkalosis<br />
3. metabolic acidosis<br />
4. excessive inhibition of carbonic anhydrase<br />
5. respiratory alkalosis</p>
<p>Item Number: 578   correct answer: 3  category: Antihypertensives<br />
41.   A diuretic agent which has been associated with hearing loss when given<br />
intravenously is:<br />
1. spironolactone<br />
2. triamterene<br />
3. ethacrynic acid<br />
4. chlorothiazide<br />
5. sucrose</p>
<p>Item Number: 579   correct answer: 1  category: Antihypertensives<br />
42.   A diuretic agent which has a steroid-like nucleus is:<br />
1. spironolactone<br />
2. triamterene<br />
3. ethacrynic acid<br />
4. chlorothiazide<br />
5. sucrose</p>
<p>Item Number: 580   correct answer: 1  category: Antihypertensives<br />
43.   The diuretic agent which acts by inhibiting <a title="aldosterone" href="http://pharmacologycorner.com/aldosterone-mechanism-of-action-video-animation/">aldosterone</a> at the distal tubular<br />
renal cell is:<br />
1. spironolactone<br />
2. triamterene<br />
3. ethacrynic acid<br />
4. chlorothiazide<br />
5. bumetanide</p>
<p>Item Number: 581   correct answer: 2  category: Antihypertensives<br />
44.   A diuretic agent which is potassium-sparing and does not depend upon the<br />
adrenal cortex for action is:<br />
1. spironolactone<br />
2. triamterene<br />
3. ethacrynic acid<br />
4. chlorothiazide<br />
5. sucrose</p>
<p>Item Number: 583   correct answer: 4  category: Antihypertensives<br />
45.   Which of the following diuretic agents may produce hypokalemic alkalosis but<br />
is a very useful drug in the treatment of volume-dependent hypertension?<br />
1. spironolactone<br />
2. triamterene<br />
3. amiloride<br />
4. chlorothiazide<br />
5. sucrose</p>
<p>Item Number: 2787   correct answer: 2  category: Antihypertensives<br />
46.   Hypercalcemia following thiazide administration is characterized by which of<br />
the following?<br />
1. hypercalciuria<br />
2. hypocalciuria<br />
3. increased serum phosphorus<br />
4. decreased serum phosphorus<br />
5. increased urinary phosphorus</p>
<p>Item Number: 2804   correct answer: 2  category: Antihypertensives<br />
47.   The diuretic agent, furosemide, is known to produce:<br />
1. decreased renin production and <a href="http://pharmacologycorner.com/aldosterone-mechanism-of-action-video-animation/">aldosterone </a>release<br />
2. increased renal blood flow and glomerular filtration rate<br />
3. redistribution of blood from the renal cortex to the medulla<br />
4. All of the above<br />
5. 1,3</p>
<p>Item Number: 3241   correct answer: 2  category: Antihypertensives<br />
48.   Complications of treatment of edema with thiazides include all of the<br />
following EXCEPT:<br />
1. hyperuricemia<br />
2. hyperkalemia<br />
3. hyperglycemia<br />
4. hyponatremia<br />
5. alkalosis</p>
<p>Item Number: 3449   correct answer: 3  category: Antihypertensives<br />
49.   Possible consequences of chlorothiazide administration include all of the<br />
following EXCEPT:<br />
1. thrombocytopenia and agranulocytosis<br />
2. jaundice, skin eruptions, and photosensitivities<br />
3. hypoglycemia<br />
4. hypokalemic nephropathy<br />
5. hyperuricemia</p>
<p>Item Number: 3543   correct answer: 4  category: Antihypertensives<br />
50.   Which of the following diuretics may cause hyperkalemia:<br />
1. ethacrynic acid<br />
2. mercurials<br />
3. thiazides<br />
4. triamterene<br />
5. acetazolamide</p>
<p>Item Number: 3911   correct answer: 3  category: Antihypertensives<br />
51.   The dominant action of the thiazide diuretics (e.g. hydrochlorothiazide)is to<br />
increase the renal excretion of sodium and chloride and an accompanying volume<br />
of water.  This results from:<br />
1. alterations in acid-base balance<br />
2. an indirect renal effect<br />
3. inhibition of the tubular mechanisms of electrolyte transport<br />
4. increased glomerular filtration rate<br />
5. inhibition of carbonic anhydrase</p>
<p>Item Number: 3919   correct answer: 3  category: Antihypertensives<br />
52.   The oral diuretics are an effective group of drugs in the treatment of<br />
hypertension. The mechanism of action mainly responsible for the reduction of<br />
blood pressure after 2 months of treatment is:<br />
1. reduction in plasma volume<br />
2. reduction in cardiac output<br />
3. drug-induced saluresis<br />
4. reduction in serum potassium concentration<br />
5. effects on the neurotransmission at adrenergic ganglions</p>
<p>Item Number: 4308   correct answer: 4  category: Antihypertensives<br />
53.   About 20 percent of adults in north America have arterial blood pressures<br />
above the normal range. The aldosterone antagonist, spironolactone, has been<br />
used to treat hypertension with some success. Side effects of spironolactone<br />
include:<br />
1. hyponatremia<br />
2. azotemia<br />
3. gynecomastia<br />
4. all of the above<br />
5. 1,3</p>
<p>Item Number: 4437   correct answer: 3  category: Antihypertensives<br />
54.   The effectiveness of which of the following diuretics is diminished in<br />
metabolic acidosis?<br />
1. triamterene<br />
2. spironolactone<br />
3. acetazolamide<br />
4. All of the above<br />
5. 1,3</p>
<p>Item Number: 4775   correct answer: 3  category: Antihypertensives<br />
55.  The inhibition of carbonic anhydrase in proximal renal tubular cells caused by<br />
acetazolamide causes a loss in urine of:<br />
1. hydrogen ions<br />
2. glucose<br />
3. bicarbonate ions<br />
4. glycine<br />
5. None of the above</p>
<p>Item Number: 7278   correct answer: 4  category: Antihypertensives<br />
56.  Complications common to ethacrynic acid and thiazides include:<br />
1. alkalosis<br />
2. potassium depletion<br />
3. hyperuricemia<br />
4. All of the above<br />
5. 1,3</p>
<p>Item Number: 7930   correct answer: 5  category: Antihypertensives<br />
57.   Hypokalemia may result from all of the following EXCEPT:<br />
1. flumethiazide<br />
2. hydrochlorothiazide<br />
3. chlorthalidone<br />
4. bendroflumethiazide<br />
5. triamterene</p>
<p>Item Number: 8226   correct answer: 5  category: Antihypertensives<br />
58.   Hypochloremic alkalosis may result from prolonged use of:<br />
1. furosemide<br />
2. mannitol<br />
3. ethacrynic acid<br />
4. All of the above<br />
5. 1,3</p>
<p>Item Number: 8320   correct answer: 2  category: Antihypertensives<br />
59.   Triamterene:<br />
1. antagonizes aldosterone<br />
2. can produce systemic hyperkalemia<br />
3. is classified as a sodium-sparing diuretic<br />
4. is of no clinical usefulness<br />
5. interferes with the diuretic activity of spironolactone</p>
<p>Item Number: 8365   correct answer: 1  category: Antihypertensives<br />
60.   Antihypertensive agents must be used with caution.  The medical condition for<br />
which spironolactone is most contraindicated is:<br />
1. renal insufficiency<br />
2. coronary insufficiency<br />
3. central depression<br />
4. liver disease<br />
5. asthma</p>
<p>Item Number: 8418   correct answer: 1  category: Antihypertensives<br />
61.   With which of the following side effects is spironolactone most closely<br />
identified with?<br />
1. hyperkalemia<br />
2. metabolic acidosis<br />
3. metabolic alkalosis<br />
4. hypoglycemia<br />
5. hypokalemia</p>
<p>Item Number: 8822   correct answer: 3  category: Antihypertensives<br />
62.   A diuretic which acts by inhibition of the sodium-hydrogen exchange is:<br />
1. furosemide<br />
2. chlormerodrin<br />
3. acetazolamide<br />
4. mannitol<br />
5. triamterene</p>
<p>Item Number: 10292   correct answer: 2  category: Antihypertensives<br />
63.   To achieve smooth reduction of blood pressure, all of the oral diuretics<br />
must be administered at least once daily.  Maximum effectiveness is achieved only<br />
after:<br />
1. 1 to 2 weeks<br />
2. 3 to 4 weeks<br />
3. 5 to 6 weeks<br />
4. 7 to 8 weeks<br />
5. 9 to 10 weeks</p>
<p>Item Number: 10293   correct answer: 3  category: Antihypertensives<br />
64.   Diuretics may reduce blood pressure through several mechanisms. The critical<br />
effect, however, appears to be:<br />
1. reduction of vascular smooth muscle reactivity<br />
2. effect on autonomic control of vascular tone<br />
3. reduction of total body sodium content<br />
4. effect on electrolyte content of arterial tissues<br />
5. reduction of plasma renin activity</p>
<p>Item Number: 11201   correct answer: 4  category: Antihypertensives<br />
65.   Gynecomastia, hyperkalemia, and menstrual abnormalities are potential adverse<br />
effects associated with:<br />
A.  amiloride<br />
B.  captopril<br />
C.  triamterene<br />
D.  spironolactone<br />
1. A,B,C<br />
2. A,C<br />
3. B,D<br />
4. D only<br />
5. All are correct</p>
<p>Item Number: 11218   correct answer: 2  category: Antihypertensives<br />
66.   Diuretics which should not be used in a patient also receiving potassium<br />
supplementation include:<br />
A.  amiloride<br />
B.  mannitol<br />
C.  triamterene<br />
D.  bumetanide<br />
1. A,B,C<br />
2. A,C<br />
3. B,D<br />
4. D only<br />
5. All are correct</p>
<p>Item Number: 11220   correct answer: 1  category: Antihypertensives<br />
67.   Metabolic alkalosis is a complication of the administration of:<br />
A.  hydrochlorothiazide<br />
B.  bumetanide<br />
C.  furosemide<br />
D.  acetazolamide<br />
1. A,B,C<br />
2. A,C<br />
3. B,D<br />
4. D only<br />
5. All are correct</p>
<p>Item Number: 13710   correct answer: 3  category: Antihypertensives<br />
68.    Which of the following drugs may be hazardous if give to a patient receiving<br />
spironolactone?<br />
1. epinephrine<br />
2. propranolol<br />
3. potassium chloride<br />
4. monoamine oxidase inhibitors<br />
5. All of the above</p>
<p>Item Number: 13715   correct answer: 1  category: Antihypertensives<br />
69.   A side effect of spironolactone, when utilized to treat hypertension is:<br />
1. hyperkalemia<br />
2. acne<br />
3. hypomagnesemia<br />
4. male pattern baldness<br />
5. bronchospasm</p>
<p>Item Number: 13823   correct answer: 1  category: Antihypertensives<br />
70.   The principle site of action of furosemide is the:<br />
1. ascending loop of Henle<br />
2. descending loop of Henle<br />
3. proximal tubule<br />
4. distal tubule<br />
5. None of the above</p>
<p>Item Number: 13824   correct answer: 3  category: Antihypertensives<br />
71.   The site of action of mannitol is:<br />
1. ascending loop of Henle<br />
2. descending loop of Henle<br />
3. proximal tubule<br />
4. distal tubule<br />
5. None of the above</p>
<p>Item Number: 14202   correct answer: 5  category: Antihypertensives<br />
72.   A diuretic which is contraindicated in a patient with hyperkalemia is:<br />
1. acetazolamide<br />
2. chlorothiazide<br />
3. ethacrynic acid<br />
4. furosemide<br />
5. spironolactone</p></blockquote>
<p><a title="USMLE pharmacology questions" href="http://pharmacologycorner.com/usmle-mcqs/">More USMLE pharmacology questions</a></p>
]]></content:encoded>
			<wfw:commentRss>http://pharmacologycorner.com/usmle-like-questions-on-antihypertensives/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Barbiturates review: a video lecture</title>
		<link>http://pharmacologycorner.com/barbiturates-review-a-video-lecture/</link>
		<comments>http://pharmacologycorner.com/barbiturates-review-a-video-lecture/#comments</comments>
		<pubDate>Sun, 15 Feb 2009 21:06:00 +0000</pubDate>
		<dc:creator>Flavio Guzmán, MD</dc:creator>
				<category><![CDATA[Anticonvulsants]]></category>
		<category><![CDATA[Neurology]]></category>
		<category><![CDATA[Pharmacology animations]]></category>
		<category><![CDATA[barbiturates]]></category>
		<category><![CDATA[pharmacology video]]></category>

		<guid isPermaLink="false">http://pharmacologycorner.com/barbiturates-review-a-video-lecture/</guid>
		<description><![CDATA[Video lecture. Great study aid to review barbiturates for your pharmacology test. Thiopental, Phenobarbital, Methohexital and Pentobarbital.]]></description>
			<content:encoded><![CDATA[<p>Video lecture series by the O2demand team. In this episode barbiturates are reviewed.</p>
<p>Mechanism of action, pharmacokinetics and properties of: Thiopental, Phenobarbital, Methohexital and Pentobarbital</p>
<p>&#160;</p>
<p><embed src="http://blip.tv/play/AdPnM5CaGA" type="application/x-shockwave-flash" width="320" height="270" allowscriptaccess="always" allowfullscreen="true"></embed></p>
<p>Great aid to review this topic for your pharmacology test, like <a href="http://pharmacologycorner.com/usmle-mcqs/">USMLE step 1</a>.</p>
]]></content:encoded>
			<wfw:commentRss>http://pharmacologycorner.com/barbiturates-review-a-video-lecture/feed/</wfw:commentRss>
		<slash:comments>3</slash:comments>
		</item>
	</channel>
</rss>

